Research and Markets: Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019 - High Prevalence of Autoimmune Disease & Increase in Awareness

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/9dbfwt/global_systemic) has announced the addition of the "Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019" report to their offering.

The Global SLE Drugs market to grow at a CAGR of 22.41% over the period 2014-2019.

To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of SLE that are available in the market.

SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.

Knowledge about the diagnosis of SLE and its treatment is growing in Europe and Asia, areas where the disease is more prevalent. In addition, numerous public awareness campaigns aimed at increasing awareness levels are also being conducted. For instance, LFA has been implementing various projects to increase federal support for lupus research and services to assist people and families affected by lupus. Similarly, SLE Lupus Foundation's program provides support services to patients and their families to cope with lupus.

According to the report, the high prevalence of autoimmune disease is a major contributor to the growth of the market. The number of people being diagnosed with SLE has been on the rise. Therefore, the demand for drugs is also increasing.

Further, the report states that the complex etiology of the disease is a major challenge in the market.

Key Vendors

- Anthera Pharmaceuticals

- BMS

- GSK

- ImmuPharma

- Merck Serono

- UCB

Other Prominent Vendors

- Amgen

- HGS

- Immunomedics

- Johnson & Johnson

- MedImmune

- Sanofi

- Teva Pharmaceutical Industries

For more information visit http://www.researchandmarkets.com/research/9dbfwt/global_systemic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals